5/1/2013

The FDA has granted Raptor Pharmaceuticals approval for its Procysbi therapy for nephropathic cystinosis in children and adult patients. The delayed-release treatment was given orphan-drug status, as the disease affects about 500 U.S. patients.

Related Summaries